Algenex Announces GMP Certification
19 avr. 2022 06h37 HE
|
Algenex SL
PRESS RELEASE Algenex Announces GMP Certification Madrid, 19 April 2022 - Algenex, a leader in the production of alternative proteins, backed by Cleon Capital and Columbus Ventures, announces that...
Algenex Announces Entry into the Food Technology Market
21 mars 2022 03h00 HE
|
Algenex SL
PRESS RELEASE Algenex Announces Entry into the Food Technology Market Madrid, 21 March 2022 - Algenex, a leader in the production of alternative proteins, backed by Cleon Capital and Columbus...
Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics
18 nov. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics Madrid and Barcelona (Spain) 18 November, 2021 – Algenex SL, a biotech company...
Commercial Adoption of Herdscreen® ASFV Antibody Test in Europe
28 oct. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Commercial Adoption of Herdscreen® ASFV Antibody Test in Europe New pen-side test allows for highly specific, sensitive detection of infected animals or contaminated pig-derived...
Algenex enters biocomponents market to provide mammalian-free production of cost efficient high-quality proteins and peptides
30 sept. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex enters biocomponents market to provide mammalian-free production of cost efficient high-quality proteins and peptides Proven technology poised to accelerate growth of emerging...
Algenex’ CrisBio® platform validated by EU and UK marketing authorization for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease
24 sept. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex’ CrisBio® platform validated by EU and UK marketing authorization for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease Madrid (Spain) & Bologna (Italy), 24...
EMA validates Algenex’ CrisBio® platform for the manufacturing of vaccines
22 juin 2021 02h00 HE
|
Algenex SL
PRESS RELEASE EMA validates Algenex’ CrisBio® platform for the manufacturing of vaccines Regulator validation supports broad application of insect-based biologics production technology CrisBio...
Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease
21 juin 2021 07h00 HE
|
Algenex SL
PRESS RELEASE Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease Madrid (Spain) and Bologna (Italy), June 21, 2021 – Algenex SL, a...
Algenex and Virbac sign international commercial licensing agreement for CrisBio®-based vaccine in major swine indication
22 févr. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex and Virbac sign international commercial licensing agreement for CrisBio®-based vaccine in major swine indication Madrid (Spain) and Carros (France), February 22, 2021 –...
Algenex inaugurates new facility with capacity to produce up to 100 million vaccine doses
24 sept. 2020 09h00 HE
|
Algenex SL
Algenex inaugurates new facility with capacity to produce up to 100 million vaccine doses New facility can support the production of up to 3.5kg of recombinant protein equivalent to around 100...